Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 12/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710420 | 0.86 | PDE5A (0.41) | PDE5AHDAC1HDAC6PDE3APDE3B | |
| SCHEMBL6712236 | 0.79 | PDE11A (0.42) | PDE5AHDAC1HDAC6 | |
| SCHEMBL6709011 | 0.74 | MTOR (0.39) | PDE5AHDAC1HDAC6HDAC2MTOR | |
| SCHEMBL6707578 | 0.72 | MTOR (0.38) | PDE5AHDAC1HDAC6HDAC2MTOR | |
| SCHEMBL6763523 | 0.72 | PDE11A (0.42) | PDE5AHDAC1HDAC6 | |
| SCHEMBL6710404 | 0.72 | MTOR (0.37) | PDE5AHDAC1HDAC6HDAC2MTOR | |
| SCHEMBL6709067 | 0.71 | PDE5A (0.36) | PDE5AHDAC1HDAC6PDE3APDE3B | |
| SCHEMBL6708899 | 0.70 | PDE5A (0.44) | PDE5AHDAC1HDAC6PDE3AHDAC2 | |
| SCHEMBL11063316 | 0.66 | PDE10A (0.50) | PDE10A | |
| SCHEMBL6901515 | 0.65 | TMIGD3 (0.45) | PDE10AALDH1A1SMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777419-B1 | EXHIBIT PHOSPHODIESTERASE V INHIBITION AND CAN BE EMPLOYED FOR THE TREATMENT OF DISORDERS OF THE CARDIOVASCULAR SYSTEM OR ERECTILE DYSFUNCTION | MERCK PATENT GMBH (DE) | 2004-08-17 | — | — | US | disclosed |
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | MERCK PATENT GMBH (DE) | 2004-04-22 | — | — | US | disclosed |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | MERCK PATENT GMBH (DE) | 2004-04-01 | — | — | US | disclosed |
| US-20040063730-A1 | Pharmacuetical formulation comprising puyrazolo[4,-3-d]pyrimidines and antithrombotics, calcium antagonists, or prostaglandins or prostaglandin derivatives | MERCK PATENT GMBH (DE) | 2004-04-01 | — | — | US | disclosed |
| US-20040023990-A1 | Use of pyrazolo[4,3-d]pyrimidines | MERCK PATENT GMBH (DE) | 2004-02-05 | — | — | US | disclosed |
| US-20040023991-A1 | Use of pyrazolo[4,3-d]pyrimidines | MERCK PATENT GMBH (DE) | 2004-02-05 | — | — | US | disclosed |
| EP-1357915-A2 | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GmbH (DE) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002062343-A2 | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | PTGIS, DPYD, PTGIR | PDE5A 9/4885HDAC1 2539/4885HDAC6 2439/4885 |
| US-20040023990-A1 | Use of pyrazolo[4,3-d]pyrimidines | P2RX3, HRH2, HRH4 | PDE5A 246/4885HDAC1 3243/4885HDAC6 3458/4885 |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | EDNRA, EDNRB, PTGIR | PDE5A 7/4885HDAC1 3376/4885HDAC6 3914/4885 |
| US-20040023991-A1 | Use of pyrazolo[4,3-d]pyrimidines | DPYD, TYMP, PNPO | PDE5A 851/4885HDAC1 3574/4885HDAC6 3361/4885 |
| US-20040063730-A1 | Pharmacuetical formulation comprising puyrazolo[4,-3-d]pyrimidines and antithrombotics, calcium antagonists, or prostaglandins or prostaglandin derivatives | PTGIS, PTGIR, PTGER1 | PDE5A 100/4885HDAC1 3726/4885HDAC6 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.